Everest Medicines

News

20 2021/05

Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer
17 2021/05

Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
06 2021/05

Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
15 2021/04

Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer
14 2021/04

Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy^® for the Treatment of Metastatic Urothelial Cancer
09 2021/04

Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy^® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
31 2021/03

Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy^® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
22 2021/03

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava^™ for the Treatment of Complicated Intra-abdominal Infections
22 2021/03

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020
19 2021/03

Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021
01 2021/03

Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
18 2021/02

Everest Medicines Appoints Kevin Guo as Chief Commercial Officer

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号